Adoptive T-cell transfer in melanoma.

Abstract:

:Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymphocytes demonstrates objective clinical responses in 50-72% of the patients, including 10-40% complete responses and was shown to produce durable disease control with long progression-free survival. Tumor-infiltrating T-lymphocyte ACT might even have curative potential as the vast majority of the complete responders are without any evidence of disease many years after treatment. Other adoptive transfer studies employ the genetic modification of T lymphocytes with genes encoding tumor-specific T cell receptors or antibody-based chimeric antigen receptors. These approaches opened numerous possibilities to treat cancers other than melanoma. In this article we will summarize the ACT strategies in melanoma, the new developments in this field and combinations with other therapies.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Itzhaki O,Levy D,Zikich D,Treves AJ,Markel G,Schachter J,Besser MJ

doi

10.2217/imt.12.143

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

79-90

issue

1

eissn

1750-743X

issn

1750-7448

journal_volume

5

pub_type

杂志文章,评审
  • Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.

    abstract::Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0266

    authors: Moreau P,Hebraud B,Facon T,Leleu X,Hulin C,Hashim M,Hu Y,Caillot D,Benboubker L,Zweegman S,Merz M,Weisel K,Salwender H,Mai EK,Goldschmidt H,Bertsch U,Vanquickelberghe V,Kampfenkel T,Boer C,Krotneva S,Proskorovsky

    更新日期:2021-02-01 00:00:00

  • Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.

    abstract::Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0154

    authors: Cala-García JD,Sierra-Bretón JD,Cavelier-Baiz JE,Faccini-Martínez ÁA,Pérez-Díaz CE

    更新日期:2020-10-01 00:00:00

  • Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.

    abstract::Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various infl...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2019-0191

    authors: Boyle JV,Lam K,Han JK

    更新日期:2020-02-01 00:00:00

  • Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis.

    abstract::A 63-year-old female presented with cholestatic liver function tests in November 2016. Screening tests were negative for other causes and liver biopsy revealed primary biliary cholangitis (PBC) with autoimmune hepatitis (AIH) overlap. Ursodeoxycholic acid and azathioprine was initiated. In September 2018 she was diagn...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0184

    authors: Bhave P,Pham A,Gordon A,Moore M

    更新日期:2020-05-01 00:00:00

  • PROSTVAC® targeted immunotherapy candidate for prostate cancer.

    abstract::Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.176

    authors: Shore ND

    更新日期:2014-01-01 00:00:00

  • Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.

    abstract::The complex homeostasis of tissues is coordinated by the cytokine network and imbalances in this network may result in chronic immune disorders. Key specific cytokines, such as TNF-alpha, IFN-alpha, IL-4 or VEGF have been demonstrated to be overproduced or abnormally released in the microenvironment of pathologic tiss...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.16

    authors: Bizzini B,Drouet B,Zagury D,Abitbol M,Burny A,Boissier MC

    更新日期:2010-05-01 00:00:00

  • JAK2 inhibition in murine systemic lupus erythematosus.

    abstract::Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations. Involvement of the kidney is a major cause of morbidity and mortality in human lupus patients and in murine models of the disease. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.20

    authors: Tagoe C,Putterman C

    更新日期:2012-04-01 00:00:00

  • Immunotherapy in prostate cancer: challenges and opportunities.

    abstract::Although treatment options for castration-resistant prostate cancer (CRPC) have increased over the last decade, there remains a need for strategies that can provide durable disease control and long-term benefit. Recently, immunotherapy has emerged as a viable and attractive strategy for the treatment of CRPC. To date,...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.101

    authors: Noguchi M,Koga N,Moriya F,Itoh K

    更新日期:2016-01-01 00:00:00

  • Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.

    abstract::Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabin...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2015-0015

    authors: Bagacean C,Zdrenghea M,Tempescul A,Cristea V,Renaudineau Y

    更新日期:2016-05-01 00:00:00

  • Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy.

    abstract::Progressive multifocal leukoencephalopathy (PML) is a rare and severe complication of natalizumab therapy in patients with multiple sclerosis and it may be accompanied by immune reconstitution inflammatory syndrome (IRIS). Here, we describe a case of abnormally severe IRIS, which occurred 2 months after natalizumab-as...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.13.155

    authors: Calvi A,De Riz M,Pietroboni AM,Ghezzi L,Maltese V,Arighi A,Fumagalli GG,Jacini F,Donelli C,Comi G,Galimberti D,Scarpini E

    更新日期:2014-01-01 00:00:00

  • The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

    abstract::While the etiology of multiple sclerosis (MS) remains unclear, research from the clinic and preclinical models identified the essential role of inflammation and demyelination in the pathogenesis of MS. Current treatments focused on anti-inflammatory processes are effective against acute episodes and relapsing-remittin...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2018-0153

    authors: Robinson RR,Dietz AK,Maroof AM,Asmis R,Forsthuber TG

    更新日期:2019-02-01 00:00:00

  • Heat-shock proteins in diagnosis and treatment: an overview of different biochemical and immunological functions.

    abstract::Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocy...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2018-0105

    authors: Milani A,Basirnejad M,Bolhassani A

    更新日期:2019-02-01 00:00:00

  • Safety evaluation of a multiallergen immunotherapy treatment in polyallergic patients. APOLO observational study.

    abstract::Aim: Assessment of safety, tolerability and changes in global clinical impression with an multiallergen immunotherapy treatment without dilutional effect in polyallergic patients. Patients & methods: This observational prospective study included patients with allergic rhinitis-rhinoconjunctivitis with or without asthm...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0187

    authors: Alba P,Moreno V,Arias-Irigoyen J,Antón M,Parra A,Gómez-Fernández MC,Madariaga B,Martínez A,Begoña L

    更新日期:2020-01-01 00:00:00

  • Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.

    abstract::Rheumatoid arthritis (RA) is a chronic inflammatory disease in which persistent inflammation of synovial tissue results in a progressive functional decline of the joint and premature mortality. TNF inhibitors were the first biological disease-modifying antirheumatic drugs (DMARDs) used to treat RA. Since then, new bio...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.26

    authors: García-Hernández MH,González-Amaro R,Portales-Pérez DP

    更新日期:2014-01-01 00:00:00

  • Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea.

    abstract:AIM:Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea. METHODS:We obtained the fecal samples of 26 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2018-0144

    authors: Liu T,Xiong Q,Li L,Hu Y

    更新日期:2019-04-01 00:00:00

  • Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.

    abstract:AIM:There is still no specific therapy for infection with the highly pathogenic avian influenza A virus (HPAI) H5N1, which caused 39 human cases with a 64% fatality rate in 2013. MATERIALS & METHODS:We prepared highly purified specific equine polyclonal immunoglobulin fragments (F(ab')2) against H5N1 and tested them f...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.14.40

    authors: Herbreteau CH,Jacquot F,Rith S,Vacher L,Nguyen L,Carbonnelle C,Lotteau V,Jolivet M,Raoul H,Buchy P,Saluzzo JF

    更新日期:2014-01-01 00:00:00

  • Safety and effectiveness of a microcrystalline tyrosine-associated mite extract immunotherapy for allergic rhinitis.

    abstract::Aim: To assess the safety and effectiveness of an allergen immunotherapy (AIT) with a microcrystalline tyrosine-associated mite allergoid in real-world patients with allergic rhinitis (AR). Materials & methods: Retrospective, multicenter study assessing the safety of AIT in patients aged 5 to 65 years with AR, with or...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0194

    authors: Sala-Cunill A,Pérez-Formoso JL,Torán-Barona C,Almeida-Sánchez ZM,Álvarez-Fernández JA,García-Núñez I,Linana-Santafé JJ,Martínez-Tadeo JA,Boronat-Barado A,Justicia JL

    更新日期:2020-09-01 00:00:00

  • Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?

    abstract::Sarcoidois is an inflammatory disease of unknown origin characterized by the abnormal accumulation of noncaseating granulomas at sites of disease activity in multiple organs throughout the body with a predilection for the lungs. Because the exact trigger that leads to disease activity is still under investigation, cur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.103

    authors: Celada LJ,Drake WP

    更新日期:2015-01-01 00:00:00

  • Tumor-associated macrophages: implications in cancer immunotherapy.

    abstract::Tumor-associated macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment. These anti-inflammatory and protumorigenic macrophages modulate the local microenvi...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0135

    authors: Petty AJ,Yang Y

    更新日期:2017-03-01 00:00:00

  • Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response.

    abstract::The neonatal phase is a transitory period characterized by an absence of memory cells, favoring a slow adaptive response prone to tolerance effects and the development of Th2-type responses. However, when appropriately stimulated, neonates may achieve an immune response comparable with adult counterparts. One strategy...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.38

    authors: de Brito CA,Goldoni AL,Sato MN

    更新日期:2009-09-01 00:00:00

  • A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up report.

    abstract:AIM:A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis a...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2016-0068

    authors: Roger A,Depreux N,Jurgens Y,Serra AT,Heath MD,Garcia G,Skinner MA

    更新日期:2016-10-01 00:00:00

  • Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer.

    abstract::Aim: To explore the value of rate of cancer progression (ROP) prior to starting PD-1 inhibitors as a predictive and prognostic biomarker. Materials & methods: Retrospective data of patients with metastatic non-small-cell lung cancer treated with second-line PD-1 inhibitors were collected. Patients were divided into tw...

    journal_title:Immunotherapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2217/imt-2018-0180

    authors: Prasanna T,Arasaratnam M,Boyer M,McNeil C,Barnet MB,Asher R,Hui R,Nagrial A,Kao S

    更新日期:2019-06-01 00:00:00

  • Antibody-based immunotherapy of solid cancers: progress and possibilities.

    abstract::Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.57

    authors: Nicodemus CF

    更新日期:2015-01-01 00:00:00

  • Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.

    abstract::Alemtuzumab (Campath®, Genzyme Corporation, MA, USA) is a potent monoclonal antilymphocyte, anti-CD52 antibody. Since the 1980s, alemtuzumab has been used extensively in organ transplantation as an induction agent - also with the aim of avoiding or reducing maintenance immunosuppression. We herein review the literatur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.68

    authors: Weissenbacher A,Boesmueller C,Brandacher G,Oellinger R,Pratschke J,Schneeberger S

    更新日期:2010-11-01 00:00:00

  • Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.

    abstract:AIM:We developed a novel approach to efficiently deliver autologous tumor antigens to the cytoplasm of dendritic cells (DC) using yeast cell wall particles (YCWP). MATERIALS AND METHODS:Loading of YCWP, leakage of protein from loaded YCWP and cytoplasmic delivery of YCWP content was assessed using fluorescent-tagged e...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0114

    authors: Hardin MO,Vreeland TJ,Clifton GT,Hale DF,Herbert GS,Greene JM,Jackson DO,Berry JE,Nichols P,Yin S,Yu X,Wagner TE,Peoples GE

    更新日期:2018-04-01 00:00:00

  • The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.

    abstract::After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death pro...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0029

    authors: Kourie HR,Awada G,Awada A

    更新日期:2017-06-01 00:00:00

  • Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.

    abstract::Hereditary angioedema (HAE) is a relatively rare autosomal dominant disorder that is typically characterized by recurrent episodes of edema in various body locations. It is most commonly caused by an inherited deficiency of functionally active C1 esterase inhibitor (C1-INH). Replacement therapy with a human plasma-der...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.33

    authors: Bork K

    更新日期:2014-01-01 00:00:00

  • The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

    abstract::NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.117

    authors: Subleski JJ,Jiang Q,Weiss JM,Wiltrout RH

    更新日期:2011-10-01 00:00:00

  • Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy.

    abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0188

    authors: Huang J,Rong L,Wang E,Fang Y

    更新日期:2021-01-01 00:00:00

  • PLAC1 immunization does not induce infertility in mice.

    abstract:AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0019

    authors: Liso A,Massenzio F,Stracci F

    更新日期:2017-05-01 00:00:00